This test maps your genetic variants in key weight-loss pathways (GIPR, FTO, and MC4R genes) and analyzes 49 peptides across 14 metabolic pathways to reveal whether tirzepatide or a dual-compound approach like GLP-Squared may work better for your body
The deep penetrating nevus
Wegovy is FDA-approved for weight management in adults with a BMI of 30, or 27 with weight related comorbidities
At our Memphis weight loss clinic, youll get real answers, expert support, and a plan that works for your life
CAS: 475466-57-0 Purity: 99% Soluble in DMSO MF: C28H37N3O3 MW: 463.61 Description GLP-1 antagonist is a selective glucagon-like peptide-1 (GLP-1) receptor antagonist
Oral Wegovy became FDA-approved in late December 2025, making it the first oral GLP-1 medication for weight loss